Myditin (Pridinol Mesilate)

Pridinol mesilate, the active ingredient in Myditin, is a centrally acting muscle relaxant presented as an oral formulation for oral use. It is used to relieve muscle spasm and musculoskeletal pain in adult patients.

GNH USA supplies Myditin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myditin, a centrally acting muscle relaxant, is employed in conditions involving involuntary muscle contraction and associated discomfort.

- Muscle spasm: reduces involuntary muscle contraction and eases associated pain. - Musculoskeletal pain: alleviates pain linked to strain or injury of muscles and joints. - Acute musculoskeletal conditions: helps restore normal muscle tone during short‑term inflammatory episodes.

Adverse reactions may occur with any centrally acting muscle relaxant.

Common Side Effects: - Dry mouth: reduced salivary secretion causing a feeling of thirst. - Drowsiness: mild sedation that may affect alertness. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

Before initiating therapy, consider the following safety measures.

- Pregnancy: safety not established; avoid use unless clearly needed. - Breastfeeding: potential excretion in milk; weigh benefits against risks. - Elderly patients: increased sensitivity to anticholinergic effects; start with lowest effective dose. - Respiratory disorders: caution in patients with asthma or COPD due to possible bronchial effects. - Driving and machinery: may cause drowsiness; advise patients to avoid operating vehicles or heavy equipment. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Pridinol mesilate can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Other anticholinergic agents: additive anticholinergic burden may cause severe dry mouth, urinary retention, or confusion. - Central nervous system depressants (e.g., benzodiazepines, opioids): risk of profound sedation and respiratory depression. - Monoamine oxidase inhibitors: potential for hypertensive episodes.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance drowsiness and impair coordination. - Antihistamines: increase anticholinergic side‑effects such as blurred vision. - Tricyclic antidepressants: may intensify anticholinergic and sedative effects.